Qurient
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Qurient is a South Korean biotech that develops entirely new prescription drugs, medicines with novel mechanisms not previously approved, targeting cancer, bacterial infections, and inflammatory diseases.
It is listed on KOSDAQ, South Korea's tech-focused stock exchange, and operates two business lines: drug research and development, and the distribution of prescription pharmaceuticals. The company's pipeline programs are all first-in-class candidates, and it earns revenue through a combination of research-and-development service fees and pharmaceutical distribution sales.
Summary is AI-generated and may contain errors · figures from DART filings
Qurient was spun off from the Korea Institut Pasteur and holds a strategic alliance with Germany's Max-Planck-Gesellschaft giving it priority review rights over cancer and autoimmune research programs.
Qurient in five facts
What does Qurient do?
Qurient is a South Korean biotech that develops entirely new prescription drugs, medicines with novel mechanisms not previously approved, targeting cancer, bacterial infections, and inflammatory diseases.
Where is Qurient listed and in which sector?
Qurient (Korean name: 큐리언트) trades under KRX code 115180 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is Qurient?
Its market capitalisation was US$613.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Qurient's latest annual revenue and operating profit?
For fiscal year 2025, Qurient reported revenue of US$5.3M, an operating loss of US$22.5M and a net loss of US$23.6M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 23.9% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Ex-rights (rights offering)Capital raise · Oct 16
- Rights offering: round 1 issue price setCapital raise · Oct 16
- ProspectusOct 16
- [Terms finalized] Securities registration statement (equity)Oct 16
- [Amended] Material event report (rights offering)
Qurient updated the terms of a new share issuance to raise US$75.6M, about 13.0% of its market value.
Capital raise · Oct 16 · 3 versions - DisclosureOct 16
- Executives/major shareholders' securities trading planOct 15
- Investor relations (IR) meetingOct 13
- [Amended] Securities registration statement (equity)Sep 29
- Investor relations (IR) meetingSep 22
- Investor relations (IR) meetingSep 22
- DisclosureSep 17
- Investor relations (IR) meetingSep 7
- Investor relations (IR) meetingSep 4
- Securities registration statement (equity)Sep 4
- [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Qurient updated its previously filed consolidated results for FY2025: revenue of US$4.74M (−23.94% year on year), an operating loss of US$20.2M and a net loss of US$21.2M.
Earnings · Mar 11 · 2 versions